To the Editor:
Thromboxane Release During Pacing-induced Angina
To the Editor:
With great interest we read the article by Lewy et al. ' reporting the release of thromboxane during pacing-induced angina. In our opinion it would have been better to calculate the thromboxane uptake in the plasma during passage through the coronary system in each patient. The estimation of the aortic-coronary sinus difference in plasma thromboxane level at each step of the procedure would have been a better indicator for thromboxane release. We performed such calculations and found that only four of Lewy's 14 patients showed marked thromboxane release during and after pacing, five had only a very slight release, two did not release at all and three had a loss of thromboxane in the coronary system. The mean aortic-coronary sinus difference measured is 0.25 pmol/ml in rest, becoming 0.15 pmol/ml during pacing and 1.1 pmol/ml soon thereafter.
We studied2 10 patients, all male, with stable exercise-induced angina and found seven to have obstructive coronary artery disease. Three had normal coronaries and served as controls. We used a protocol similar to Lewy's, but measured the release of d thromboglobulin, a platelet-specific protein released during platelet activation. Our results show a mean aortic-coronary sinus difference of 3.0 ng/ml in patients at rest, becoming 6.0 ng/ml during pacing. However, our controls also showed a marked rise, from 12.3 ng/ml at rest to 20.3 ng/ml during pacing.
Unfortunately, Lewy 
We are not certain how Drs. Verheugt and Serruys used the data in table 1 to recalculate aortic-coronary sinus "differences" and would not interpret a negative "difference" to mean "loss" of thromboxane in the coronary system. Did they assign values of zero or 0.5 pmol/ml where table 1 indicated "less than 0.5 pmol/ml?" As indicated in the second paragraph of our Results, these entries were arbitrary and equivalent to "nondetectable" levels. The Results section, the legend to figure 1 and table 2 all explain that the highest possible value for these samples (0.5 pmol/ml) was used to calculate means for the group studied and the expected effect of this approach would be to "minimize the apparent increases in pacing induced thromboxane release." Thus, the analysis was weighted toward proving the null hypothesis, but we still found p = 0.027 level of significance between coronary sinus and thromboxane release and negative lactate extraction after pacing.
Another point raised by Verheugt and Serruys deserves comment. Unlike lactate, both coronary sinus and arterial thromboxane levels rose in response to pacing. Thromboxane is not known to be a substrate for myocardial metabolism, and we doubt that concepts of gradient or uptake will have meaning for this compound, unlike lactate. Hence, calculations of aortic-coronary sinus differences for the whole group or individually as suggested by Verheugt and Serruys are not recommended, particularly as values below the detection limit cannot be assigned an accurate figure. We feel the reperfused coronary bed washes out the inactivated thromboxane /3 metabolite, which then appears (in our study) in either coronary sinus samples, arterial samples, or both. The substance undoubtedly recirculates systemically for some time in an unchanged form. 2 Although table 1 shows arteriographic data for the patients studied, there is no grounds for suggesting "major discordance" between the thromboxane release and "the severity of coronary abnormalities" observed. For example, Levine et al.3 report that platelet factor 4 is detectable in coronary artery disease patients, but not in healthy volunteers defined arteriographically. In their study, however, the degree of coronary vascular involvement did not correlate with platelet factor 4 levels. Therefore it seems more reasonable to use dynamic criteria and, in our controls with or without coronary artery disease, when lactate extraction did not fall, thromboxane release did not occur.
Finally, the cause of pacing-produced fluxes in 3 thromboglobulin reported by Verheugt and Serruys in both controls and patients is unclear. It appears they did not sample in the washout phase at all, where,B thromboglobulin might have continued to rise in coronary artery disease subjects but not in the controls. Furthermore, the two compounds (,/ thromboglobulin and thromboxane)
are not comparable, as thromboglobulin is neither vasoactive nor does it initiate an amplifying sequence of its own release by previously unstimulated platelets.
Certainly the study of coronary thromboxane release in angina patients should develop methodically according to restrictions imposed by its own assay methods and physiology. In this way it may come to serve as a guide for clinical trials of antiplatelet agents in patients with coronary insufficiency.
